Investors capitalize on the panic to focus on the long-term story!
The multi-year collaboration with Pfizer on the Lyme disease vaccine could grant the companies market leadership upon approval!
Reading Time: 1 minute
On April 7, the overall market was panic-sold due to the uncertain developments regarding US tariff policy and potential countermeasures from other countries. Particularly speculative and cyclical stocks were dynamically sold off. However, throughout the day, recovery movements began to emerge. The share price reaction for Valneva SE (i.) was particularly positive. The biotech company impresses with its already approved vaccines against Chikungunya, Cholera, and Japanese Encephalitis (JE). Furthermore, it is conducting research on vaccines for Shigella,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
